Endometrial hyperplasia: a modern view of the problem
AbstractThe endometrium is a unique tissue that undergoes cyclical changes every month, the essence of which is proliferation, secretion and decidualization under the influence of steroid hormones of the ovaries. One of the pathological transformations is endometrial hyperplasia. The urgency of the problem is due to an increase in the prevalence of endometrial cancer, the precursor of which is endometrial hyperplastic processes.
Aim. To conduct a systematic review of the data available in the modern literature on the prevalence, risk factors, pathogenesis and treatment of patients suffering from endometrial hyperplastic process.
Material and methods. To create a review, an analysis of the Pubmed, Embase, Cochrane databases was undertaken and international reviews over the past few years and the results of randomized controlled trials were taken.
Result. The article presents modern ideas about the prevalence, risk factors, pathogenesis and therapy of endometrial hyperplasia according to domestic and foreign literature.
Conclusion. Despite the centuries-old study of endometrial hyperplasia, questions about the etiology, pathogenesis, risk factors, and management tactics of patients remain fully understood and require further study.
Keywords:endometrial hyperplasia; endometrial cancer; pathogenesis; risk factors
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Orazov M.R., Mikhaleva L.M., Mullina I.A. Endometrial hyperplasia: a modern view of the problem. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2022; 10 (3): 62–7. DOI: https://doi.org/10.33029/2303-9698-2022-10-3-62-67 (in Russian)
REFERENCES
1. Clinical recommendations of the Ministry of Health of Russia «Endometrial hyperplasia». Moscow, 2021. (in Russian)
2. Reed S.D., Newton K.M., Clinton W.L., et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009; 200: 678.e1–6.
3. American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society, 2021.
4. Vilos G.A., Oraif A., Vilos A.G., Ettler H., et al. Long-term clinical outcomes following resectoscopic endometrial ablation of non-atypical endomential hyperplasia in women with abnormal uterine bleeding. J Minim Invasive Gynecol. 2015; 22 (1): 66–77.
5. He Y., Wang Y., Zhou R., et al. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer. Int J Gynecol Cancer. 2020; Oct 13. DOI: https://doi.org/10.1136/ijgc-2020-001570
6. Parkash V., Fadare O., Tornos C., McCluggage W.G. Committee Opinion No. 631. Endometrial intraepithelial neoplasia. Obstet Gynecol. 2015; 126 (4): 897.
7. Orazov M.R., Mikhaleva L.M., Mullina I.A., Leffad L.M. Pathogenesis of recurrent endometrial hyperplasia without atypia. Trudniy patsient [Difficult Patient]. 2021; 19 (6): 36–9. DOI: https://doi.org/10.224412/2074-1005-2021-6-36-39 (in Russian)
8. van der Meer A.C., Hanna L.S. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clin Obes. 2017; 7 (1): 54–7.
9. Orazov M.R., Krasnopol’skaya K.V., Mikhaleva L.M., Mullina I.A. Views on the pathogenetic mechanisms of endometrial hyperplastic processes development. Trudniy patsient [Difficult Patient]. 2021; 19 (3): 35–8. DOI: https://doi.org/10.224412/2074-1005-2021-3-35-38 (in Russian)
10. Orazov M.R., Krasnopol’skaya K.V., Mikhaleva L.M., Semenov P., Mullina I.A. Algorithm of actions of a clinician in case of hyperplastic processes of the endometrium. Trudniy patsient [Difficult Patient]. 2021; 19 (3): 39–42. DOI: https://doi.org/10.224412/2074-1005-2021-3-39-42 (in Russian)
11. Orazov M.R., Mikhaleva L.M., Orekhov R.E., Mullina I.A. Prevention of endometrial hyperplasia without atypia in women of reproductive age. Ginekologiya [Gynecology]. 2021; 23 (5): 454–8. DOI: https://doi.org/10.26442/20795696.2021.5.201217 (in Russian)
12. Trimble C.L., Method M., Leitao M., Lu K., Ioffe O., Hampton M., et al. Management of endometrial precancers. Obstet Gynecol. 2012; 120: 1160–75.
13. Singh G., Puckett Y. Endometrial hyperplasia. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2022 Jan 2.
14. Kiselev V.I., Sidorova I.S., Unanyan A.L., Muyzhnek E.L. Hyperplastic processes of the organs of the female reproductive system: theory and practice. Moscow: MEDPRAKTIKA-M, 2010: 468 p. (in Russian)
15. Song D., Feng X., Zhang Q., Xia E., Xiao Y., Xie W., et al. Prevalence and confounders of chronic endometritis in premenopausal women with abnormal bleeding or reproductive failure. Reprod Biomed Online. 2018; 36 (1): 78–83. DOI: https://doi.org/10.1016/j.rbmo.2017.09.008
16. Sanderson P.A., Critchley H.O.D., Williams A.R.W., Arends M.J., Saunders P.T.K. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017; 23 (2): 232–54. DOI: https://doi.org/10.1093/humupd/dmw042
17. Suidan R.S., He W., Sun C.C., Zhao H., Fleming N.D., Ramirez P., et al. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017; 145 (1): 55–60. DOI: https://doi.org/10.1016/j.ygyno.2017.01.025
18. Mitsuhashi A., Uehara T., Hanawa S., Shozu M. Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer. 2017; 25 (5): 1495–501. DOI: https://doi.org/10.1007/s00520-016-3554-y
19. Wartko P.D., Beck T.L., Reed S.D., Mueller B.A., Hawes S.E. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017; 28 (8): 819–28. DOI: https://doi.org/10.1007/s10552-017-0908-9
20. Orazov M.R. Debating points of endometrium hyperplasia case management. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2016; (3): 46–58. (in Russian)
21. Adamyan L.V. (ed.). Combined benign tumors and hyperplastic processes of the uterus (myoma, adenomyosis, endometrial hyperplasia). Draft clinical guidelines for the management of patients. Moscow: Nauchniy tsentr akusherstva, ginekologii i perinatologii im. V.I. Kulakova Minzdrava Rossii, 2015: 92 р. (in Russian)
22. Furness S., Roberts H., Marjoribanks J., Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012; 8: CD000402.
23. Kaminski P., Bobrowska K., Pietrzak B., Bablok L., Wielgos M. Gynecological issues after organ transplantation. Neuro Endocrinol Lett. 2008; 29 (6): 852–6.
24. Niskakoski A., Pasanen A., Porkka N., Eldfors S., Lassus H., Renkonen- Sinisalo L., et al. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: shared origin of synchronous carcinomas. Gynecol Oncol. 2018; 150 (1): 92–8.
25. Mills A.M., Sloan E.A., Thomas M., Modesitt S.C., Stoler M.H., Atkins K.A., et al. Clinicopathologic comparison of Lynch syndrome-associated and «Lynch-like» endometrial carcinomas identified on universal screening using mismatch repair protein immunohistochemistry. Am J Surg Pathol. 2016; 40 (2): 155–65.
26. Orazov M.R., Radzinsky V.E., Arakelov S.E., Khamoshina M.B., Nosenko E.N., Dukhin A.O., et al. Risk factors for endometrial hyperplastic processes in women of reproductive age. Trudniy patsient [Difficult Patient]. 2019; 17 (5): 19–21. (in Russian)
27. Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27 (1): e8. DOI: https://doi.org/10.3802/jgo.2016.27.e8
28. Kadirogullari P., Atalay C.R., Ozdemir O., Sari E.M. Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia. J Clin Diagn Res. 2015; 9 (10): QC10–4.
29. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds). Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena – filial FGBU «FMITs radiologii» Minzdrava Rossii, 2020: 252 p. (in Russian)
30. Iversen M.L., Dueholm M. Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9–14 years. Eur J Obstet Gynecol Reprod Biol. 2018; 222: 171–5.
31. Morice P., Leary A., Creutzberg C., Abu-Rustum N., Darai E. Endometrial cancer. Lancet. 2016; 387 (10 023): 1094–108.
32. Orazov M.R., Mikhaleva L.M., Mullina I.A. Predicting recurrent endometrial hyperplasia. Trudniy patsient [Difficult Patient]. 2021; 19 (7): 6–8. DOI: https://doi.org/10.224412/2074-1005-2021-7-6-8 (in Russian)
33. Auclair M.H., Yong P.J., Salvador S., Thurston J., Colgan T.T.J., Sebastia- nelli A. Guideline No. 390 – classification and management of endometrial hyperplasia. J Obstet Gynaecol Can. 2019; 41 (12): 1789–800.
34. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68 (1): 7–30.
35. URL: https://www.who.int/
36. Koskas M., Uzan J., Luton D., Rouzier R., Darai E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014; 101: 785–94.
37. Sato M., Arimoto T., Kawana K., et al. Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma. Mol Clin Oncol. 2016; 4: 492–6.
38. Penner K.R., Dorigo O., Aoyama C., et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012; 124: 542–8.
39. Travaglino A., Raffone A., Saccone G., Insabato L., Mollo A., De Placido G., et al. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019; 98 (9): 1086–99. DOI: https://doi.org/10.1111/aogs.13587 Epub 2019 Mar 18. PMID: 30793281.
40. Gibson D.A., Saunders P.T. Estrogen dependent signaling in reproductive tissues – a role for estrogen receptors and estrogen related receptors. Mol Cell Endocrinol. 2012; 348 (2): 361–72.
41. Gibson D.A., Saunders P.T. Endocrine disruption of oestrogen action and female reproductive tract cancers. Endocr Relat Cancer. 2014; 21 (2): T13–31.
42. Hu K., Zhong G., He F. Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer. 2005; 15 (3): 537–41.
43. Chakravarty D., Srinivasan R., Ghosh S., Rajwanshi A., Gopalan S. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. Appl Immunohistochem Mol Morphol. 2008; 16 (6): 535–42.
44. Sletten E.T., Arnes M., Lysa L.M., Moe B.T., Straume B., Orbo A. Prediction of relapse after therapy withdrawal in women with endometrial hyperplasia: a long-term follow-up study. Anticancer Res. 2017; 37: 2529–36.
45. Diep C.H., Ahrendt H., Lange C.A. Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes. Steroids. 2016; 114: 48–58.
46. Latta E., Chapman W.B. PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol. 2002; 14 (1): 59–65.
47. Allison K.H., Tenpenny E., Reed S.D., Swisher E.M., Garica R.L. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol. 2008; 16 (4): 329–43.
48. Steinbakk A., Gudlaugsson E., Aasprong O.G., Skaland I., Malpica A., Feng W., et al. Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol. 2011; 204 (4): 357.e1–12.
49. Marshall E., Lowrey J., MacPherson S., Maybin J.A., Collins F., Critchley H.O., et al. In silico analysis identifies a novel role for androgens in the regulation of human endometrial apoptosis. J Clin Endocrinol Metab. 2011; 96 (11): E1746–55.
50. Vaskivuo T.E., Stenbäck F., Tapanainen J.S. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer. 2002; 95 (7): 1463–71.
51. Mitselou A., Ioachim E., Kitsou E., Vougiouklakis T., Zagorianakou N., Makrydimas G., et al. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In Vivo. 2003; 17 (5): 469–77.
52. Aganezova N.V., Aganezov S.S. Obesity and female reproductive health. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2016; (6): 18–25. DOI: https://doi.org/10.18565/aig.2016.6.18-25 (in Russian)
53. Sletten E.T., Arnes M., Lysa L.M., Larsen M., Orbo A. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study. BJOG. 2019; 126 (7): 936–43. DOI: https://doi.org/10.1111/1471-0528.15579 Epub 2019 Jan 25. PMID: 30548528.
54. van der Putten L.J.M., van Hoof R., Tops B.B.J., Snijders M.P.L.M., van den Berg-van Erp S.H., van der Wurff A.A.M., et al. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis. 2017; 38 (3): 329–35.
55. Erdem B., Aşıcıoğlu O., Seyhan N.A., Peker N., Ülker V., Akbayır Ö. Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia? Int J Surg. 2018; 53: 350–3.
56. Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/BSGE Joint Guideline. February 2016.
57. Emons G., Beckmann M.W., Schmidt D., et al. New who classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015; 75: 135–6.
58. Wheeler D.T., Bristow R.E., Kurman R.J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007; 31: 988–98.
59. Dijkhuizen F.P., Mol B.W., Brolmann H.A., et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia. Cancer. 2000; 89: 1765–72.
60. Singh G., Puckett Y. Endometrial hyperplasia. 2021 Apr 13. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2021.
61. Lacey J.V. Jr, Sherman M.E., Rush B.B., et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010; 28: 788–92.
62. Loose D.S., Stancel G.M. Estrogens and progestins. In: L.L. Brunton, J.S. Lazo, K.L. Parker (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006: 1541–71.
63. El Behery M.M., Saleh H.S., Ibrahiem M.A., Kamal E.M., Kassem G.A., Mohamed Mel S. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015; 22 (3): 329–34. DOI: https://doi.org/10.1177/1933719114542014 Epub 2014 Jul 6. PMID: 25001020.
64. Ozolinya L.A, Lapina I.A., Boldina E.B., Lutsenko N.N. Treatment of patients with endometrial hyperplasia combined with uterine myomas. Lechebnoe delo [Medical Care]. 2011; (2): 34–9. (in Russian)
65. Nooh A.M., Abdeldayem H.M., Girbash E.F., et al. Depo-Provera versus norethisterone acetate in management of endometrial hyperplasia without atypia. Reprod Sci. 2016; 23: 448–54.
66. Moradan S., Nikkhah N., Mirmohammadkhanai M. Comparing the administration of letrozole and megestrol acetate in the treatment of women with simple endometrial hyperplasia without atypia: a randomized clinical trial. Adv Ther. 2017; 34: 1211–20.
67. Moore E., Shafi M. Endometrial hyperplasia. Obstet Gynaecol Reprod Med. 2013; 23: 88–93.
68. Beavis A.L., Cheema S., Holschneider C.H., et al. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep. 2015; 13: 71–5.
69. Concin N., Matias-Guiu X., Vergote I., Cibula D., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol. 2021; 154: 327–53. DOI: https://doi.org/10.1016/j.radonc.2020. 11.018
70. Gallos I.D., Yap J., Rajkhowa M., et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2012; 207: 266.e1–12.
71. Simpson A.N., Feigenberg T., Clarke B.A., et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol. 2014; 133: 229–33.
72. Orbo A., Arnes M., Vereide A.B., et al. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2016; 123: 1512–9.
73. Park J.Y., Lee S.H., Seong S.J., et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol. 2013; 129: 7–11.
74. Gressel G.M., Parkash V., Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015; 131: 234–9.
75. Gallos I.D., Shehmar M., Thangaratinam S., Papapostolou T.K., Coomara- samy A., Gupta J.K. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2010; 203 (6): 547.e1–10.